10
Oct

Novartis has expanded its relationship with the U.K.’s Oxford BioMedica, signing a deal worth up to $90 million that will support the drugmaker’s efforts in CAR-T immunotherapies.

…read more

Source: Novartis taps Oxford BioMedica in $90M immuno-oncology deal

    

0 No comments